| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2007.14.9898 |
| P698 | PubMed publication ID | 18421053 |
| P50 | author | Leonard B. Saltz | Q37830465 |
| P2093 | author name string | Arie Figer | |
| Fernando Rivera | |||
| Stephen Clarke | |||
| Mikhail Lichinitser | |||
| Jim Cassidy | |||
| Werner Scheithauer | |||
| Sheryl Koski | |||
| Tsai-Shen Yang | |||
| Eduardo Díaz-Rubio | |||
| Florin Sirzén | |||
| Ralph Wong | |||
| Felix Couture | |||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | colorectal cancer | Q188874 |
| capecitabine | Q420207 | ||
| oxaliplatin | Q422327 | ||
| colorectal carcinoma | Q25493920 | ||
| P304 | page(s) | 2006-2012 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer | |
| P478 | volume | 26 |
| Q52986105 | (18)F-Fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) for the early detection of response to neoadjuvant chemotherapy for locally advanced rectal cancer. |
| Q34180260 | 5-Fluorouracil or capecitabine in the treatment of advanced colorectal cancer: a pooled-analysis of randomized trials |
| Q33425826 | A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer |
| Q59813330 | A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients |
| Q42770955 | A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. |
| Q36814369 | A Randomised Controlled Phase II Trial of the Combination of XELOX with Thalidomide for the First-line Treatment of Metastatic Colorectal Cancer |
| Q46288489 | A comparison of XELOX with FOLFOX-4 as first-line treatment for metastatic colorectal cancer |
| Q33436476 | A multi-institutional feasibility study of S-1/oxaliplatin plus bevacizumab in patients with advanced/metastatic colorectal cancer: the HiSCO-02 prospective phase II study |
| Q57088820 | A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection |
| Q43197898 | A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma |
| Q44649659 | A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies |
| Q35033392 | A phase I dose escalation study of oxaliplatin plus oral S-1 and pelvic radiation in patients with locally advanced rectal cancer (SHOGUN trial). |
| Q45228150 | A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer |
| Q42041063 | A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. |
| Q53518550 | A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study. |
| Q33430668 | A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract |
| Q33399530 | A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer |
| Q36105171 | A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study |
| Q33931775 | A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. |
| Q54577684 | A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer. |
| Q34682635 | A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer |
| Q33998072 | A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer |
| Q53839706 | A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. |
| Q33613721 | A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). |
| Q87765485 | A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes |
| Q36742214 | A prospective feasibility study to evaluate neoadjuvant-synchronous S-1 with radiotherapy for locally advanced rectal cancer: A multicentre phase II trial |
| Q36778075 | A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902). |
| Q36131174 | A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial |
| Q45923777 | A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer. |
| Q34344012 | A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer |
| Q35113026 | A retrospective study of first-line combination chemotherapy in advanced colorectal cancer: a Korean single-center experience |
| Q41495258 | AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin |
| Q37468876 | Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. |
| Q64084991 | Acute abdominal obstruction: Colon stent or emergency surgery? An evidence-based review |
| Q36230665 | Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials |
| Q42695547 | Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial |
| Q26774704 | Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis |
| Q53555698 | Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. |
| Q33398998 | Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations |
| Q33710593 | Alternating systemic and hepatic artery infusion therapy for resected liver metastases from colorectal cancer: a North Central Cancer Treatment Group (NCCTG)/ National Surgical Adjuvant Breast and Bowel Project (NSABP) phase II intergroup trial, N99 |
| Q46275226 | Ameliorative Effect of Caffeic Acid on Capecitabine-Induced Hepatic and Renal Dysfunction: Involvement of the Antioxidant Defence System. |
| Q94453610 | An Observational Study of Team Management Approach for CapeOX Therapy in Patients with Advanced and Recurrent Colorectal Cancer: SMILE Study (The Study of Metastatic colorectal cancer to investigate the Impact of Learning Effect) |
| Q43954035 | An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. |
| Q92512348 | Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer |
| Q33820851 | Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy |
| Q35051678 | Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer |
| Q44136582 | Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial. |
| Q30922171 | Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review |
| Q33396369 | Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach |
| Q35767943 | Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study |
| Q43062212 | Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer |
| Q36611697 | Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. |
| Q38260176 | Bevacizumab: a review of its use in advanced cancer |
| Q37633765 | Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer |
| Q33757046 | Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma |
| Q86039372 | Can grade 2 neutropenia predict the risk of grade 3 neutropenia in metastatic colorectal cancer patients treated with chemotherapy? |
| Q37821286 | Capecitabine for locally advanced and metastatic colorectal cancer: A review |
| Q34236005 | Capecitabine in gastric cancer |
| Q24633039 | Capecitabine in the management of colorectal cancer |
| Q46542857 | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study |
| Q34639725 | Capecitabine plus oxaliplatin compared with 5-fluorouracil plus oxaliplatin in metastatic colorectal cancer: Meta-analysis of randomized controlled trials |
| Q36385665 | Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer |
| Q85177862 | Capecitabine-based chemotherapy for metastatic colorectal cancer |
| Q60922862 | Capecitabine-induced hypertriglyceridemia: a rare but clinically relevant treatment-related adverse event |
| Q34649050 | Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. |
| Q37242667 | Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. |
| Q38002127 | Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. |
| Q34637479 | Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial |
| Q26768402 | Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy |
| Q37802537 | Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection |
| Q43259379 | Chemotherapy of colorectal cancer |
| Q34873168 | Chemotherapy plus percutaneous radiofrequency ablation in patients with inoperable colorectal liver metastases |
| Q37799918 | Chemotherapy: which drug and when? |
| Q53085418 | Chronomodulated oxaliplatin plus Capecitabine (XELOX) as a first line chemotherapy in metastatic colorectal cancer: A Phase II Brunch regimen study. |
| Q28079074 | Chronotherapy with low-dose modified-release prednisone for the management of rheumatoid arthritis: a review |
| Q37481190 | Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients |
| Q38095836 | Clinical dilemmas and a review of strategies to manage drug shortages |
| Q37092129 | Colon cancer and the elderly: from screening to treatment in management of GI disease in the elderly. |
| Q55924124 | Colorectal cancer |
| Q34352595 | Colorectal cancer in Chinese patients: current and emerging treatment options. |
| Q33735234 | Colorectal cancer: from prevention to personalized medicine. |
| Q36084353 | Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously |
| Q99605181 | Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments |
| Q33395485 | Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial |
| Q36598736 | Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer |
| Q41231221 | Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer |
| Q92486851 | Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer |
| Q34410650 | Comparison of the clinical courses and chemotherapy outcomes in metastatic colorectal cancer patients with and without active Mycobacterium tuberculosis or Mycobacterium kansasii infection: a retrospective study |
| Q64115864 | Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine |
| Q42186139 | Complete Response of Isolated Para-aortic Lymph Node Recurrence from Rectosigmoid Cancer Treated by Chemoradiation Therapy with Capecitabine/Oxaliplatin plus Bevacizumab: A Case Report |
| Q46098962 | Complete Response of Para-Aortic and Lateral Pelvic Lymph Node Recurrence of Rectal Cancer Treated to S-1 Monotherapy |
| Q91774215 | Context-Specific Economic Evaluation for Molecular Pathology Tests: An Application in Colorectal Cancer in the West of Scotland |
| Q35125643 | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial |
| Q43480717 | Cost analysis of adjuvant therapy with XELOX or FOLFOX4 for colon cancer |
| Q58883872 | Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden – A clinical practice model approach |
| Q33874203 | Cost implications of new treatments for advanced colorectal cancer. |
| Q33955955 | Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. |
| Q51060956 | Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer. |
| Q33970042 | Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patients |
| Q38628257 | Current and advancing treatments for metastatic colorectal cancer |
| Q37771244 | Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. |
| Q34991689 | DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer. |
| Q33630882 | Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status |
| Q39041183 | Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles |
| Q42145925 | Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases? |
| Q34317249 | Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study |
| Q57758061 | ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making |
| Q53043230 | Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. |
| Q50797877 | Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. |
| Q35885143 | Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer |
| Q37729193 | Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer |
| Q30316930 | Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised co |
| Q35678109 | Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer |
| Q33428086 | Efficacy and Safety of Capecitabine and Oxaliplatin (CapOX) as an Adjuvant Therapy in Japanese for Stage II/III Colon Cancer in a Group at High Risk of Recurrence in Retrospective Study |
| Q90290560 | Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer |
| Q64110863 | Efficacy of Neoadjuvant Chemotherapy with Capecitabine plus Oxaliplatin in the Treatment of Locally Advanced Sigmoid Colon Cancer Invading the Urinary Bladder: A Report of Three Cases |
| Q26865057 | Efficacy of S-1 vs capecitabine for the treatment of gastric cancer: a meta-analysis |
| Q35196171 | Efficacy of adding bevacizumab in the first-line chemotherapy of metastatic colorectal cancer: evidence from seven randomized clinical trials |
| Q33849656 | Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients |
| Q37338244 | Efficacy of goshajinkigan for oxaliplatin-induced peripheral neuropathy in colorectal cancer patients |
| Q61448632 | Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens |
| Q92652642 | Elucidating the Reprograming of Colorectal Cancer Metabolism Using Genome-Scale Metabolic Modeling |
| Q38155482 | Emerging treatments in recurrent and metastatic colorectal cancer. |
| Q30317520 | Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial |
| Q42696006 | Epidermal growth factor receptor and metastatic colorectal cancer: insights into target therapies |
| Q92185841 | Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer |
| Q33777576 | Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective peritoneal surface disease severity score (PSDSS) for peritoneal carcinomatosis of colorectal origin |
| Q37372475 | Evolution of nonsurgical therapy for colorectal cancer |
| Q37360585 | Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy |
| Q37738171 | Evolving treatment of advanced colorectal cancer. |
| Q35932040 | Excision Repair Cross-complementation Group 1 is a Prognostic Biomarker in Patients with Colorectal Cancer Receiving Chemotherapy |
| Q38171776 | FOLFOX 4 combined with herbal medicine for advanced colorectal cancer: a systematic review. |
| Q38806782 | Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min |
| Q50949890 | Fatal adverse drug reactions of anticancer drugs detected by all-case post-marketing surveillance in Japan. |
| Q35563197 | First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis |
| Q35705210 | First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study |
| Q55058836 | Gene-expression profiles correlate with the efficacy of anti-EGFR therapy and chemotherapy for colorectal cancer. |
| Q39961051 | Health utility scores of colorectal cancer based on societal preference in Japan. |
| Q43276118 | Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? |
| Q42003363 | Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases |
| Q39922489 | Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades |
| Q47132740 | Impact of the individualization of the first-line chemotherapy for advanced colorectal cancer based on collagen gel droplet-embedded drug sensitivity test |
| Q37619856 | Important molecular genetic markers of colorectal cancer. |
| Q53641435 | Increased pre-surgical numbers of endothelial progenitor cells and circulating endothelial cells in colorectal cancer fail to predict outcome. |
| Q35173700 | Initial hepatic artery infusion and systemic chemotherapy for asymptomatic colorectal cancer with un-resectable liver metastasis |
| Q36396031 | Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings |
| Q90334350 | Integrative Herbal Medicine for Chemotherapy-Induced Peripheral Neuropathy and Hand-Foot Syndrome in Colorectal Cancer: A Systematic Review and Meta-Analysis |
| Q46869425 | Intermittent versus continuous erlotinib with concomitant modified "XELOX" (q3W) in first-line treatment of metastatic colorectal cancer: correlation with serum amphiregulin and transforming growth factor alpha. |
| Q42937632 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). |
| Q30470164 | Irinotecan-induced dysarthria. |
| Q40087710 | Is intensive chemotherapy safe for rural cancer patients? |
| Q82420834 | Ischemic colitis after capecitabine plus cisplatin treatment in advanced gastric cancer |
| Q36300533 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer |
| Q37946252 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. |
| Q36324953 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. |
| Q92776508 | Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer |
| Q37406381 | Knockdown of KLK11 inhibits cell proliferation and increases oxaliplatin sensitivity in human colorectal cancer |
| Q42627821 | Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial |
| Q58874339 | Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study |
| Q64257150 | Long-term survival of an elderly female with metastatic colon cancer after treated with capecitabine monotherapy |
| Q43124351 | Looking ahead: what will change in colorectal cancer treatment? |
| Q34229432 | Maintenance therapy with capecitabine in patients with resected pancreatic adenocarcinoma after adjuvant therapy: a retrospective cohort study |
| Q38591664 | Management of a patient with metastatic colorectal cancer and liver metastases |
| Q38081864 | Management of advanced colorectal cancer, Part 1. |
| Q38057086 | Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. |
| Q27026129 | Management of locally advanced and metastatic colon cancer in elderly patients |
| Q55032398 | Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). |
| Q33849034 | Management of stage IV rectal cancer: palliative options |
| Q83367201 | Meaningfullness and duration of palliative chemotherapy with regard to the quality of life of palliative patients |
| Q46038493 | Medical Oncology: Second-line XELOX or FOLFOX-4 for metastatic colorectal cancer. |
| Q42874419 | Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer? |
| Q35076194 | Medical treatment of advanced colorectal cancer in 2009. |
| Q38562812 | Meta-Analysis of Oxaliplatin-Based Chemotherapy Combined With Traditional Medicines for Colorectal Cancer: Contributions of Specific Plants to Tumor Response |
| Q34608222 | Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer |
| Q34664272 | Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |
| Q37642801 | Metastatic colorectal cancer: recent advances in its clinical management |
| Q42124995 | Metformin enhances TRAIL-induced apoptosis by Mcl-1 degradation via Mule in colorectal cancer cells |
| Q48580029 | Monitoring trifluridine incorporation in the peripheral blood mononuclear cells of colorectal cancer patients under trifluridine/tipiracil medication |
| Q46156144 | Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. |
| Q88001745 | Neoadjuvant CapeOx therapy followed by sphincter-preserving surgery for lower rectal cancer |
| Q39906058 | Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial |
| Q47769444 | Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial |
| Q55367746 | New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. |
| Q37094989 | Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer |
| Q37875058 | Optimal management of metastatic colorectal cancer: current status |
| Q55135995 | Optimization of drug delivery systems for intraperitoneal therapy to extend the residence time of the chemotherapeutic agent. |
| Q24239911 | Oral versus intravenous fluoropyrimidines for colorectal cancer |
| Q38650502 | Oral versus intravenous fluoropyrimidines for colorectal cancer. |
| Q42651373 | Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan. |
| Q50943809 | Outcome and safety of self-expandable metallic stents for malignant colon obstruction: a Korean multicenter randomized prospective study. |
| Q38947007 | Overall Survival and Metastasis Resections in Patients with Metastatic Colorectal Cancer Using Electronic Medical Records |
| Q34136267 | Overview of radiation therapy for treating rectal cancer |
| Q37484326 | Overview of systemic therapy for colorectal cancer |
| Q43139831 | Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium |
| Q88288687 | Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment |
| Q37242664 | Oxaliplatin-based chemotherapy in the management of colorectal cancer |
| Q39803653 | Oxaliplatin-induced neuropathy in colorectal cancer |
| Q36288022 | Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. |
| Q37965616 | Oxaliplatin: a review of approved uses. |
| Q38167675 | Palliative treatment of metastatic colorectal cancer: what is the optimal approach? |
| Q51682922 | Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. |
| Q42870250 | Patients With Locally Advanced and Metastatic Colorectal Cancer Treated With Capecitabine Versus 5-Fluorouracil as Monotherapy or Combination Therapy With Oxaliplatin: A Cost Comparison |
| Q36303226 | Patients with pathological stage N2 rectal cancer treated with early adjuvant chemotherapy have a lower treatment failure rate |
| Q50922149 | Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. |
| Q34731381 | Personalized colon cancer care in 2010. |
| Q38296666 | Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement |
| Q34036665 | Personalizing medicine for metastatic colorectal cancer: current developments |
| Q44488353 | Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: implications for health-care utilization in Australia. |
| Q39786290 | Phase 1 study on S-1 and oxaliplatin therapy as an adjuvant after hepatectomy for colorectal liver metastases |
| Q91260303 | Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study) |
| Q53641063 | Phase I clinical and pharmacokinetic study of S-1 plus oral leucovorin in patients with metastatic colorectal cancer. |
| Q38066339 | Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer |
| Q33403227 | Phase I trial of oxaliplatin plus S-1 chemotherapy in patients with metastatic colorectal cancer |
| Q34549722 | Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer |
| Q42814145 | Phase I/II study of a 3‐week cycle of irinotecan and S‐1 in patients with advanced colorectal cancer |
| Q50998049 | Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy. |
| Q34165276 | Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer |
| Q36201465 | Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer |
| Q41559464 | Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer. |
| Q37166391 | Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study |
| Q33751177 | Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer |
| Q89184549 | Phase II study of S-1 plus oxaliplatin 130 mg/m2 in Japanese patients with advanced gastric cancer |
| Q33391561 | Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis |
| Q33386361 | Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer |
| Q45000278 | Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer |
| Q33428967 | Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer |
| Q43048706 | Phase II study of pre-operative radiotherapy with capecitabine and oxaliplatin for rectal cancer and carcinoembryonic antigen as a predictor of pathological tumour response |
| Q35766292 | Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study |
| Q53067038 | Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. |
| Q33408836 | Phase II study of topotecan and bevacizumab in advanced, refractory non--small-cell lung cancer |
| Q50443737 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). |
| Q98289686 | Photothermal therapy technology of metastatic colorectal cancer |
| Q38728118 | Predicting Outcome and Therapy Response in mCRC Patients Using an Indirect Method for CTCs Detection by a Multigene Expression Panel: A Multicentric Prospective Validation Study. |
| Q37544605 | Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer |
| Q26738655 | Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options |
| Q47611002 | Preventive effect of pre-warming, hot compress, and pH adjustment in oxaliplatin-induced venous pain |
| Q37780016 | Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. |
| Q33620052 | Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer |
| Q28074175 | RAS and BRAF in metastatic colorectal cancer management |
| Q44794355 | Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases |
| Q82949813 | Radiofrequency ablation as an adjunct to systemic chemotherapy for colorectal pulmonary metastases |
| Q35739538 | Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC) |
| Q90521680 | Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study) |
| Q35884411 | Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy |
| Q33624491 | Recent Advances in Targeting the EGFR Signaling Pathway for the Treatment of Metastatic Colorectal Cancer |
| Q90412840 | Recent Strategies and Paradigm Shift in Management of Hepatic Metastasis from Colorectal Cancer |
| Q89338392 | Rechallenge with oxaliplatin and peripheral neuropathy in colorectal cancer patients |
| Q34180997 | Repeated transarterial chemoembolisation using different chemotherapeutic drug combinations followed by MR-guided laser-induced thermotherapy in patients with liver metastases of colorectal carcinoma |
| Q33455278 | Reporting of adverse events in randomized controlled trials of highly active antiretroviral therapy: systematic review |
| Q37560960 | Retrospective analysis of capecitabine and oxaliplatin (XELOX) plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer |
| Q89793537 | Retrospective analysis of the efficacy of cytokine-induced killer cell immunotherapy combined with first-line chemotherapy in patients with metastatic colorectal cancer |
| Q87065902 | Retrospective comparison of CAPOX and FOLFOX dose intensity, toxicity, and clinical outcomes in the treatment of metastatic colon cancer |
| Q40751962 | Risk Factors Exacerbating Hand-Foot Skin Reaction Induced by Capecitabine plus Oxaliplatin with or without Bevacizumab Therapy. |
| Q34333852 | Role of Bcl-xL/Beclin-1 in synergistic apoptotic effects of secretory TRAIL-armed adenovirus in combination with mitomycin C and hyperthermia on colon cancer cells |
| Q37230238 | Role of oxaliplatin in the treatment of colorectal cancer |
| Q28068817 | Role of targeted therapy in metastatic colorectal cancer |
| Q50164024 | S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase 3, non-inferiority trial |
| Q55318920 | S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT stud |
| Q87437188 | S-1 in colorectal cancer: a new standard of care? |
| Q34897322 | S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial |
| Q33750949 | Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer. |
| Q84453461 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin |
| Q38216008 | Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer? |
| Q37723248 | Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials |
| Q38851937 | Simultaneous Assessment of the Efficacy and Toxicity of Marine Mollusc-Derived Brominated Indoles in an In Vivo Model for Early Stage Colon Cancer. |
| Q53724796 | Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials. |
| Q38204673 | Standing the test of time: targeting thymidylate biosynthesis in cancer therapy |
| Q35768446 | Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer |
| Q49581883 | Subclinical thiamine deficiency in patients with abdominal cancer |
| Q41953360 | Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab |
| Q41307728 | Successful treatment with s-1 and oxaliplatin combination therapy in an elderly patient with metastatic colorectal cancer initially presenting with membranous nephropathy |
| Q48219440 | Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. |
| Q38017942 | Summary of current therapeutic options for peritoneal metastases from colorectal cancer |
| Q34005111 | Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer |
| Q58614342 | Systemic Therapy for Patients with Colorectal Cancer: State of the Art |
| Q34982764 | Systemic therapy for elderly patients with gastrointestinal cancer. |
| Q38059634 | Systemic treatment of gastrointestinal cancer in elderly patients |
| Q36038603 | TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients |
| Q42365964 | Targeted nanoparticles for colorectal cancer. |
| Q37158228 | Targeted therapeutic agents for colorectal cancer |
| Q54962055 | Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities. |
| Q33916021 | Targeting cancers in the gastrointestinal tract: role of capecitabine |
| Q49056479 | Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise? |
| Q90533493 | The Drug Shortage Crisis in the United States: Impact on Cancer Pharmaceutical Safety |
| Q38473718 | The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer |
| Q42700710 | The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials |
| Q36792350 | The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer |
| Q82619911 | The central vein access port and catheter in outpatient chemotherapy for colorectal cancer: a retrospective study of 101 patients |
| Q36334518 | The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902) |
| Q35583683 | The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development |
| Q34122777 | The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study |
| Q38487996 | The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials. |
| Q64078576 | The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study |
| Q55354894 | The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer. |
| Q37400010 | The role of targeted therapy in the treatment of advanced colorectal cancer |
| Q37348288 | The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer |
| Q37427386 | Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer |
| Q34577462 | Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction |
| Q37081059 | Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience |
| Q37225720 | Treatment in advanced colorectal cancer: what, when and how? |
| Q90159537 | Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline |
| Q38050375 | Treatment of colorectal cancer in older patients |
| Q37855303 | Treatment recommendations for metastatic colorectal cancer |
| Q37318093 | Tumor biology and cancer therapy - an evolving relationship |
| Q48529729 | Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer |
| Q36706109 | Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer |
| Q37815612 | Update on capecitabine alone and in combination regimens in colorectal cancer patients |
| Q39438479 | Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review study |
| Q89823531 | VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study |
| Q40225061 | Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer |
| Q48200047 | Value of ablation therapy in the treatment of lung metastases |
| Q34363544 | Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. |
| Q42944805 | When More is Worse in Clinical Research and Clinical Practice |
| Q37839084 | XELOX in colorectal cancer: a convenient option for the future? |
| Q34630237 | XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. |
| Q33429923 | XELOX vs. FOLFOX in metastatic colorectal cancer: An updated meta-analysis |
| Q84725494 | Yiqi zhuyu decoction combined with FOLFOX-4 as first-line therapy in metastatic colorectal cancer |
| Q83178582 | [Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer] |
| Q81965398 | [Systemic treatment of advanced colorectal cancer] |
| Q45990468 | [Therapeutic use and profile of toxicity of the FOLFOX4 regimen]. |
| Q34013539 | miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase |
Search more.